Colorectal With Associated Risk Factors Clinical Trial
— DParcoursDigOfficial title:
Prospective Evaluation of a Program for Early Identification of Needs and Multidisciplinary Intervention in Supportive Care in Digestive Oncology - DISSPO Parcours Dig' Study
| Verified date | November 2022 |
| Source | Institut Curie |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Patients with advanced gastrointestinal (GI) cancers are very often sarcopenic/malnourished at diagnosis (> 60% of cases) and at high risk of rapid clinical deterioration. These patients have important supportive care needs that represent a major challenge for improving treatment tolerance and patient survival and health-related quality of life (HRQoL). Malnutrition and sarcopenia (muscle wasting and dysfunction) are associated with an increased risk of death, complications from chemotherapy, infections, emergency procedures and hospitalizations, and increased costs of care. Therefore, malnutrition and sarcopenia represent a major clinical target in GI cancers. Interventions targeting malnutrition/sarcopenia should be implemented as early as possible in patients' pathways, these syndromes being reversible at early stages but not at late stages. A multidisciplinary assessment at diagnosis and therapeutic approach combining nutritional support and and adapted physical activity (APA) in addition to anticancer treatments should be systematically implemented in patients with advanced GI cancers. This type of intervention complies with the standards recommended by the National Cancer Institute (INCa) to promote the practice of physical activity during and after treatment in oncology.
| Status | Completed |
| Enrollment | 30 |
| Est. completion date | October 5, 2022 |
| Est. primary completion date | October 5, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Signed and dated informed consent, 2. Age = 18 years (no superior limit), 3. Histologically confirmed (1) non-colorectal cancer (esophagus, stomach, liver/bile ducts, pancreas, neuroendocrine carcinoma) or (2) colorectal with associated risk factors i.e. ECOG PS 2 (defining significant limitation in daily activities), and/or weight loss = 5% in 1 month or = 10% in 6 months (defining malnutrition/HAS 2019), 4. Advanced disease not amenable to surgery, radiation, or combined modality therapy with curative intent (previous resection of primary tumor allowed), treated with first-line chemotherapy for advanced disease (previous [neo]adjuvant chemo[radio]therapy allowed); or resectable/potentially resectable disease receiving a triplet chemotherapy regimen in a peri-operative setting (e.g. FOLFIRINOX, FLOT) (moderate risk at frailty score) 5. Patients able to attend for administration of chemotherapy, 6. Life expectancy = 3 months, 7. Registration in a National Health Care System (Couverture Maladie Universelle [CMU] included). Exclusion Criteria: 1. Other active non gastro-intestinal cancers 2. Any medical (including psychiatric, musculoskeletal, or neurological) condition contra-indicating exercise practice, 3. Pregnancy or breastfeeding, 4. Protected adults (individuals under guardianship by court order). Note: participation to another concomitant clinical trial is allowed, but the patient must inform the Investigator and get an authorization from the Sponsor. |
| Country | Name | City | State |
|---|---|---|---|
| France | Institut Curie | Paris |
| Lead Sponsor | Collaborator |
|---|---|
| Institut Curie |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Program faisability | Program feasibility will be satisfactory if = 80% of patients with advanced GI cancers included in the program complete the baseline, W4 and W8 assessments | 12 months | |
| Secondary | Dimensions of EORTC QLQ-C30 | EORTC QLQ-C30 completion | 12 months | |
| Secondary | Fatigue measured by Visual Analogue Scale (VAS) | Visual Analogue Scale (VAS) completion, a score form 0 to 10 will be given | 12 months | |
| Secondary | Pain measured by VAS and analgesics consumption | VAS completion and analgesics consumption report, a score form 0 to 10 will be given and report of analgesics consumption will be given by name and dose | 12 months | |
| Secondary | Nutritional status/inflammation measure | weight in kilograms, body mass index will be reported in BMI in kg/m^2, food intakes | 12 months | |
| Secondary | Physical condition assessed | International Physical Activity Questionnaire (IPAQ), | 12 months | |
| Secondary | Geriatric assessment if age = 70 | G8 score from 0 to 17 | 12 months | |
| Secondary | Chemotherapy tolerance assessed | toxicities (using Common Terminology Criteria for Adverse Events [CTCAE v5.0]) | 12 months | |
| Secondary | Progression Free Survival and Overall Survival | Progression Free Survival and Overall Survival | 12 months | |
| Secondary | Patient's satisfaction measured by VAS | VAS completion with a score from 0 to 10 | 12 months |